Wu Jing, Shi Yong-Quan, Wu Kai-Chun, Zhang De-Xin, Yang Jing-Hua, Fan Dai-Ming
Institute of Gastrointestinal Diseases Research, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, Shannxi Province, China.
World J Gastroenterol. 2003 Jan;9(1):59-64. doi: 10.3748/wjg.v9.i1.59.
To explore the influence of angiostatin up-regulation on the biologic behavior of gastric cancer cells in vitro and in vivo, and the potential of angiostatin gene therapy in the treatment of human gastric cancer.
Mouse angiostatin cDNA was subcloned into the eukaryotic expression vector pcDNA3.1(+) and identified by restriction endonucleases digestion and sequencing. The recombinant vector pcDNA3.1(+)-angio was transfected into human gastric cancer cells SGC7901 with liposome and paralleled with the vector control and the mock control. Angiostatin transcription and protein expression were examined by RT-PCR and Western blot in the stable cell lines selected by G418. Cell proliferation and growth in vitro of the three groups were observed respectively under microscope, cell number counting and FACS. The cells overexpressing angiostatin, vector transfected and untreated were respectively implanted subcutaneously into nude mice. After 30 days the size of tumors formed was measured, and microvessel density count (MVD) in the tumor tissues was assessed by immunohistochemistry with the primary anti-vWF antibody.
The recombinant vector pcDNA3.1(+)-angio was confirmed with the correct sequence of mouse angiostatin under the promoter CMV. After 30 d of transfection and selection with G418, macroscopic resistant cell clones were formed in the experimental group transfected with pcDNA 3.1(+)-angio and the vector control. But no untreated cells survived in the mock control. Angiostatin mRNA transcription and protein expression were detected in the experimental group. No significant differences were observed among the three groups in cell morphology, cell growth curves and cell cycle phase distributions in vitro. However, in nude mice model, markedly inhibited tumorigenesis and slowed tumor expansion were observed in the experimental group as compared with the controls, which was paralleled with decreased microvessel density in and around tumor tissues (P<0.05).
Angiostatin does not directly inhibit human gastric cancer cell proliferation and growth in vitro, but exerts its anti-tumor functions through antiangiogenesis in a paracrine way in vivo.
探讨血管抑素上调对胃癌细胞体内外生物学行为的影响,以及血管抑素基因治疗在人类胃癌治疗中的潜力。
将小鼠血管抑素cDNA亚克隆至真核表达载体pcDNA3.1(+),经限制性内切酶消化和测序鉴定。用脂质体将重组载体pcDNA3.1(+)-血管抑素转染至人胃癌细胞SGC7901,并与载体对照和空载体对照平行。通过RT-PCR和Western blot检测在经G418筛选的稳定细胞系中血管抑素的转录和蛋白表达。分别在显微镜下观察、细胞计数和流式细胞术检测三组细胞在体外的增殖和生长情况。将过表达血管抑素的细胞、转染载体的细胞和未处理的细胞分别皮下接种于裸鼠。30天后测量形成的肿瘤大小,并用抗vWF抗体免疫组化法评估肿瘤组织中的微血管密度计数(MVD)。
重组载体pcDNA3.1(+)-血管抑素在CMV启动子下具有正确的小鼠血管抑素序列。经G418转染和筛选30天后,转染pcDNA 3.1(+)-血管抑素的实验组和载体对照组形成了肉眼可见的抗性细胞克隆。但空载体对照组中未处理的细胞无一存活。实验组检测到血管抑素mRNA转录和蛋白表达。三组细胞在体外的细胞形态、细胞生长曲线和细胞周期阶段分布无显著差异。然而,在裸鼠模型中,与对照组相比,实验组观察到明显的肿瘤发生抑制和肿瘤生长减缓,同时肿瘤组织及其周围的微血管密度降低(P<0.05)。
血管抑素在体外不直接抑制人胃癌细胞的增殖和生长,但在体内通过旁分泌方式通过抗血管生成发挥其抗肿瘤作用。